CA3119531A1 - Anellosomes for delivering secreted therapeutic modalities - Google Patents

Anellosomes for delivering secreted therapeutic modalities Download PDF

Info

Publication number
CA3119531A1
CA3119531A1 CA3119531A CA3119531A CA3119531A1 CA 3119531 A1 CA3119531 A1 CA 3119531A1 CA 3119531 A CA3119531 A CA 3119531A CA 3119531 A CA3119531 A CA 3119531A CA 3119531 A1 CA3119531 A1 CA 3119531A1
Authority
CA
Canada
Prior art keywords
nucleic acid
sequence
anellosome
genetic element
orf1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3119531A
Other languages
English (en)
French (fr)
Inventor
Erica Gabrielle Weinstein
Avak Kahvejian
Simon Delagrave
Nathan Lawrence YOZWIAK
Kevin James LEBO
Fernando Martin DIAZ
Dhananjay Maniklal NAWANDAR
Ryan D. TEDSTONE
Jared David PITTS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flagship Pioneering Innovations V Inc
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of CA3119531A1 publication Critical patent/CA3119531A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3119531A 2018-12-12 2019-12-12 Anellosomes for delivering secreted therapeutic modalities Pending CA3119531A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862778866P 2018-12-12 2018-12-12
US201862778869P 2018-12-12 2018-12-12
US62/778,869 2018-12-12
US62/778,866 2018-12-12
PCT/US2019/065919 WO2020123773A2 (en) 2018-12-12 2019-12-12 Anellosomes for delivering secreted therapeutic modalities

Publications (1)

Publication Number Publication Date
CA3119531A1 true CA3119531A1 (en) 2020-06-18

Family

ID=69160343

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3119531A Pending CA3119531A1 (en) 2018-12-12 2019-12-12 Anellosomes for delivering secreted therapeutic modalities

Country Status (11)

Country Link
US (2) US20230048858A1 (https=)
EP (1) EP3894568A2 (https=)
JP (2) JP2022512395A (https=)
KR (1) KR20210131309A (https=)
CN (1) CN113631717A (https=)
AU (1) AU2019396520A1 (https=)
BR (1) BR112021009379A2 (https=)
CA (1) CA3119531A1 (https=)
IL (1) IL283778A (https=)
MX (1) MX2021006943A (https=)
WO (1) WO2020123773A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4337235A4 (en) * 2021-05-12 2025-07-02 Flagship Pioneering Innovations V Inc ANELLOVECTORS AND METHODS OF USE

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11624061B2 (en) 2017-04-28 2023-04-11 Agrospheres, Inc. Compositions and methods for enzyme immobilization
BR112020005803A2 (pt) 2017-09-25 2020-12-01 Agrospheres, Inc. composições e métodos para produção e administração moduláveis de produtos biológicos
BR112021011124A2 (pt) * 2018-12-12 2022-03-15 Flagship Pioneering Innovations V Inc Anelossomos e métodos de uso
JP2022513459A (ja) * 2018-12-12 2022-02-08 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド タンパク質代替治療モダリティを送達するためのアネロソーム
JP2023530451A (ja) * 2020-06-17 2023-07-18 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド アネロウイルスを同定し及び特徴付ける方法並びにその使用
JP2023548838A (ja) * 2020-10-29 2023-11-21 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド ニワトリ貧血ウイルス（ｃａｖ）に基づくベクター
KR20230146560A (ko) * 2021-02-08 2023-10-19 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 하이브리드 aav-아넬로벡터
CN118284411A (zh) * 2021-10-12 2024-07-02 旗舰先锋创新V股份有限公司 新颖的指环载体组合物和方法
EP4415695A4 (en) * 2021-10-12 2025-11-26 Flagship Pioneering Innovations V Inc NEW ANELLOVECTOR COMPOSITIONS AND METHODS
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於將治療劑遞送至骨之組成物和方法
TW202529819A (zh) 2023-10-13 2025-08-01 美商旗艦先鋒創新公司 組織特異性指環載體(anellovector)遞送
CN117695410B (zh) * 2024-02-06 2024-05-03 中国人民解放军军事科学院军事医学研究院 CRISPR/Cas9纳米抗菌剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395472B1 (en) * 1999-02-05 2002-05-28 Abbott Laboratories Methods of utilizing the TT virus
AU2014361781B2 (en) * 2013-12-12 2021-04-01 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
CN108291216B (zh) * 2015-09-24 2022-09-16 宾夕法尼亚州大学信托人 用于治疗补体介导的疾病的组合物和方法
IL271275B1 (en) * 2017-06-13 2026-04-01 Flagship Pioneering Innovations V Inc Preparations containing croons and their uses
BR112020007405A2 (pt) * 2017-10-18 2020-12-08 Regenxbio Inc. Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4337235A4 (en) * 2021-05-12 2025-07-02 Flagship Pioneering Innovations V Inc ANELLOVECTORS AND METHODS OF USE

Also Published As

Publication number Publication date
WO2020123773A9 (en) 2020-08-27
WO2020123773A2 (en) 2020-06-18
MX2021006943A (es) 2021-11-17
EP3894568A2 (en) 2021-10-20
JP2022512395A (ja) 2022-02-03
KR20210131309A (ko) 2021-11-02
BR112021009379A2 (pt) 2021-08-17
CN113631717A (zh) 2021-11-09
IL283778A (en) 2021-07-29
US20230048858A1 (en) 2023-02-16
JP2024100936A (ja) 2024-07-26
WO2020123773A3 (en) 2020-07-23
AU2019396520A1 (en) 2021-05-27
US20260009050A1 (en) 2026-01-08

Similar Documents

Publication Publication Date Title
CA3119531A1 (en) Anellosomes for delivering secreted therapeutic modalities
CA3119814A1 (en) Anellosomes for delivering protein replacement therapeutic modalities
CA3121528A1 (en) Anellosomes and methods of use
CA3119339A1 (en) Anellosomes for delivering intracellular therapeutic modalities
KR20220155981A (ko) 미성숙 종결 코돈-매개 장애를 치료하기 위한 방법 및 조성물
CA3066750A1 (en) Compositions comprising curons and uses thereof
US20240148807A1 (en) Oncolytic virus (oncolytic immunotherapy) capable of effectively treating even metastatic cancer while ensuring safety, with expression control system providing optimal expression level of mounted immunogenic gene
JP2022115976A (ja) ユートロフィン遺伝子を標的とした筋ジストロフィーの治療方法
CN110393791B (zh) hnRNPA2B1的抗感染作用及其应用
CN115160413A (zh) 一种新型冠状病毒疫苗
KR20230041686A (ko) 아넬로바이러스를 확인 및 특징화하는 방법 및 이의 용도
CN116444661A (zh) 一种广谱中和SARS-CoV-2的中和抗体P186-1H2及其应用
KR20230124682A (ko) Rna를 봉입하는 아넬로바이러스 캡시드의 시험관 내어셈블리
CN114423868B (zh) 用于将大载量基因和蛋白质递送到人细胞中的原核-真核杂交病毒载体
EP4048798B1 (en) Adenovirus comprising a modified adenovirus hexon protein
CN117247447A (zh) 一种广谱中和SARS-CoV-2的中和抗体P2S-2E9及其应用
CN116355081A (zh) 一种广谱中和SARS-CoV-2的中和抗体P2-1D5及其应用
EP4029515B1 (en) Anti-infection effects of hnrnpa2b1 and use thereof
EP2128261A1 (en) A recombinant adenovirus comprising recombinant khp50 gene and preparation method and uses thereof
WO2025241027A1 (en) Vectors encapsidating nucleic acids, production methods and uses thereof
CN116769734A (zh) 一种缺氧微环境响应溶瘤病毒株的构建及其应用
TW202529819A (zh) 組織特異性指環載體(anellovector)遞送
CN121824676A (zh) 外泌体膜靶向肽及其在合成富含il-10的外泌体中的用途
WO2024243134A2 (en) Engineered bacteriophage particle and method of gene therapy by using same
CN117164703A (zh) 一种广谱中和SARS-CoV-2的中和抗体P5S-2B10及其应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220726

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241121

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250320

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250401